Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content
Fig. 3 | Immunity & Ageing

Fig. 3

From: CD57+ EMRA CD8+ T cells in cancer patients over 70: associations with prior chemotherapy and response to anti-PD-1/PD-L1 therapy

Fig. 3

Association of CD8+ T cells senescence with prior chemotherapy and response to anti-PD-1/PD-L1 therapy: A The senescence of CD8+ T cells, indicated by EMRA, CD57, and granzyme B (GRZB) expression, is analyzed in relation to prior chemotherapy exposure. The data are presented as a proportion of the total CD8+ T cell population. B The frequency of CD57+ EMRA CD8+ T cells (cut-off 10%) is compared based on pre-exposure to chemotherapy. C The proportion of CD57+ EMRA and CD57+ GRZB+ EMRA CD8.+ T cells (cut-off 10%) is shown in relation to treatment response, categorized as progressive disease (PD), partial response (PR), or stable disease (SD)

Back to article page

Immunity & Ageing

ISSN: 1742-4933

Contact us